Mounjaro (tirzepatide) affects both GLP-1 and GIP receptors, raising concerns that its digestive-slowing effects may be stronger or more complex than earlier GLP-1 drugs.
Motility Disorders Reported With Mounjaro
Patients have reported:
- gastroparesis
- severe constipation
- ileus
- generalized GI dysmotility
Dual-Action Mechanism Concerns
Mounjaro’s dual hormone action may:
- intensify appetite suppression
- further slow GI transit
- disrupt gut-brain signaling
In some patients, this appears to lead to prolonged or severe motility impairment.
Common Symptoms
- persistent nausea and vomiting
- inability to eat normally
- abdominal pain and distension
- dehydration
Legal Context
Mounjaro motility disorder claims focus on:
- severity of digestive injury
- permanence of symptoms
- failure to warn of extreme motility suppression
➡️ Related: Motility Disorders
Mounjaro-related motility disorders can result in long-term digestive disability. These injuries are now actively evaluated within GLP-1 litigation.